Developer docs
API playgroundTry for free, no card

Search company profiles

Autolus

Full company profile

uuid0002x96

Namestring
Autolus
Legal namestring
Autolus Therapeutics plc
Websiteurl
autolus.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Autolus Therapeutics plc is a UK-domiciled (London), NASDAQ-listed (AUTL) clinical-to-commercial biopharmaceutical company founded in 2014 by Dr Martin Pule and spun out of University College London. The company designs and manufactures autologous CAR T cell therapies using a proprietary advanced cell programming platform centred on Chimeric Antigen Receptors, proprietary viral vectors, and semi-automated cell manufacturing processes. Its sole commercial product is AUCATZYL (obecabtagene autoleucel / obe-cel), a CD19-directed CAR T therapy approved by the U.S. FDA in 2024, the UK MHRA in 2025, and the European Commission in 2025 for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL); the UK commercial launch occurred in January 2026 following a positive NICE recommendation. Underlying the commercial business is a pipeline of next-generation CAR T candidates (AUTO1/22, AUTO3, AUTO4, AUTO5, AUTO6NG, AUTO8, AUTO9) targeting additional hematologic malignancies, solid tumors, and autoimmune indications including systemic lupus erythematosus and progressive multiple sclerosis.

Autolus generates revenue primarily through sales of AUCATZYL to certified treatment centers and hospital networks in the United States, United Kingdom, and European Union. FY2025 net product revenue was $74.3M, growing to $26.2M in Q1 2026 (versus $9.0M in Q1 2025), with 2026 full-year guidance of $120-135M. Manufacturing is anchored at the Nucleus, a 70,000 sq ft commercial facility in Stevenage, UK, designed for approximately 2,000 batches per year (with capacity doubling planned for 2026), supported by wholly-owned operating subsidiaries in the United States (Autolus Inc., Delaware/Gaithersburg), United Kingdom (Autolus Limited, England), and Germany (Autolus GmbH, Weil am Rhein). The company supplements direct sales with the AutolusAssist U.S. patient support program covering travel, housing, and meal logistics.

Since founding in 2014 with a £30M Series A from Syncona, Autolus has progressed through Series B (£40M, 2016), Series C ($80M, 2018), a NASDAQ IPO in June 2018 ($160.4M), and multiple subsequent public offerings (totaling several hundred million dollars through 2024), supplemented by strategic capital from Blackstone Life Sciences (up to $250M announced in 2021) and a 2024 CAR T collaboration with BioNTech. As of April 2026, the company initiated a 13% workforce reduction to save $15M annually beginning in 2027 alongside $8M of restructuring charges, reflecting a focus on operational efficiency as commercial ramp accelerates.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CAR T cell therapy, autologous cell therapy, oncology biopharmaceuticals, T cell programming, cell therapy manufacturing
Industry2 codes
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
CAR T Cell Therapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Subscription Recurring
TypeSubscription Recurring
Description

No source material with WX-format source IDs was provided to support revenue model details.

Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1AUCATZYL
Description

Autolus' approved autologous CD19 CAR T-cell therapy (obecabtagene autoleucel / obe-cel) for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

autolus.com
+7 more records
Core offering1 text field

Autolus develops, manufactures, and commercializes autologous CAR T cell therapies for cancer and autoimmune diseases. Its lead and only currently approved product is AUCATZYL (obecabtagene autoleucel / obe-cel), a CD19-directed CAR T cell therapy approved by the US FDA in 2024 and subsequently by the UK MHRA and European Commission in 2025 for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. The company also advances a pipeline of next-generation CAR T product candidates (AUTO1/22, AUTO3, AUTO4, AUTO5, AUTO6NG, AUTO8, AUTO9) targeting hematologic malignancies, T-cell lymphomas, solid tumors, and autoimmune indications, supported by an in-house commercial-scale manufacturing facility, The Nucleus, in Stevenage, UK.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Autolus Therapeutics is a clinical-to-commercial biopharmaceutical company built around a single unified advanced cell programming platform that powers a portfolio of autologous CAR T cell therapy candidates. The only commercially approved product is AUCATZYL (obecabtagene autoleucel, also known as obe-cel), a CD19-directed CAR T therapy for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL), which received US FDA approval in 2024 and subsequent UK MHRA conditional marketing authorization and European Commission approval in 2025, with UK commercial launch in January 2026. The same platform is extended across a pipeline of next-generation product candidates: AUTO1/22 and AUTO3 (dual CD19/CD22 targeting for B-cell malignancies), AUTO4 and AUTO5 (TRBC1- and TRBC2-targeting for T-cell lymphoma), AUTO6NG (GD2 targeting for neuroblastoma), AUTO8 (dual BCMA/CD19 targeting for multiple myeloma), and AUTO9 (preclinical AML candidate), with obe-cel additionally being evaluated in systemic lupus erythematosus. Together, AUCATZYL forms the approved commercial anchor while AUTO1/22, AUTO3, AUTO4, AUTO5, AUTO6NG, AUTO8, and AUTO9 represent the modular pipeline extensions of Autolus's core CAR T cell programming technology.

Product and service8 records
1AUCATZYL (obecabtagene autoleucel; obe-cel)
CategoryCore commercial product (approved autologous CAR T cell therapy)
Description

Autologous CD19-directed CAR T cell therapy approved by the US FDA (2024), UK MHRA (2025 conditional marketing authorisation), and European Commission (2025) for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (B-ALL); commercially launched in the UK in January 2026. Obe-cel is also being evaluated for indication expansion including systemic lupus erythematosus (SLE).

2AUTO1/22
CategoryPipeline product candidate (CAR T cell therapy)
Description

Dual-targeting CD19/CD22 CAR T cell therapy candidate in Phase 1 development for pediatric relapsed/refractory B-cell ALL, designed to reduce antigen-negative relapse by simultaneously engaging both CD19 and CD22 on B-cell malignancies.

3AUTO3
CategoryPipeline product candidate (CAR T cell therapy)
Description

Dual-targeting CD19/CD22 CAR T cell therapy candidate in development for B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL), leveraging Autolus's advanced cell programming platform.

4AUTO4
CategoryPipeline product candidate (CAR T cell therapy)
Description

TRBC1-targeting CAR T cell therapy candidate in development for T-cell malignancies, including peripheral T-cell lymphoma (PTCL), using a T-cell receptor beta chain constant region 1 (TRBC1) approach to selectively target malignant T-cell clones.

5AUTO5
CategoryPipeline product candidate (CAR T cell therapy)
Description

TRBC2-targeting CAR T cell therapy candidate in development for T-cell lymphoma, complementing AUTO4 by targeting the TRBC2-positive T-cell population.

6AUTO6NG
CategoryPipeline product candidate (CAR T cell therapy)
Description

GD2-targeting CAR T cell therapy candidate in development for neuroblastoma and other GD2-expressing solid tumors (MAGNETO Phase 1), incorporating next-generation enhancements to Autolus's advanced cell programming platform.

7AUTO8
CategoryPipeline product candidate (CAR T cell therapy)
Description

Dual-targeting BCMA/CD19 CAR T cell therapy candidate in development for multiple myeloma, intended to address BCMA antigen escape by simultaneously targeting CD19.

8AUTO9
CategoryPipeline product candidate (preclinical CAR T cell therapy)
Description

Preclinical CAR T cell therapy candidate in development for acute myeloid leukemia (AML), expanding Autolus's platform into myeloid malignancies.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage allogeneic CAR T developer using TALEN gene editing, with multiple programs in B-ALL and other hematologic malignancies overlapping with Autolus's pipeline.

2Bristol Myers Squibb
TypeDirect peer
Description

Markets Breyanzi (CD19 CAR T) and Abecma (BCMA CAR T) following the Celgene/Juno acquisitions, directly overlapping Autolus's CD19 and pipeline BCMA (AUTO8) franchises; deep commercial reach into US treatment centers.

TypeEmerging player
Description

Cell therapy company co-marketing Abecma (idecabtagene vicleucel) with BMS and continuing CAR T pipeline work; operates a similar autologous cell therapy commercial model to Autolus.

TypeDirect peer
Description

Markets Yescarta and Tecartus, the leading commercial CD19 CAR T cell therapies, in direct competition with Autolus's AUCATZYL in B-cell hematologic malignancies; same autologous CAR T modality, same customer base of academic treatment centers.

TypeEmerging player
Description

Clinical-stage allogeneic CAR T developer using CRISPR-based gene editing; overlapping target indications (B-ALL, B-NHL) with Autolus and a potential longer-term modality competitor.

TypeEmerging player
Description

Pioneering allogeneic ('off-the-shelf') CAR T cell therapies targeting CD19 and BCMA; if successful, would represent a modality-level competitive threat to Autolus's autologous CAR T platform.

7Johnson & Johnson (Janssen)
TypeDirect peer
Description

Co-markets Carvykti (ciltacabtagene autoleucel) with Legend Biotech for multiple myeloma, directly competing with Autolus's AUTO8 BCMA/CD19 program; large pharma with global commercialization capability.

TypeEmerging player
Description

Developing base-edited CAR T cell therapies for hematologic malignancies and rare diseases; an emerging modality competitor to Autolus's engineered T-cell platform.

TypeEmerging player
Description

Developing gene-edited allogeneic CAR T cell therapies (e.g., CTX112 for CD19) with partners Vertex and Roche; represents a next-generation competitive modality to Autolus's autologous constructs.

TypeDirect peer
Description

Pioneer of CAR T cell therapy with Kymriah (tisagenlecleucel), the first FDA-approved CAR T, directly competing with AUCATZYL in B-ALL and DLBCL; broad biopharma with deep commercial and manufacturing infrastructure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles31 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Autolus

CAR T Cell Therapyautolus.com

What Autolus does

Autolus Therapeutics plc is a UK-domiciled (London), NASDAQ-listed (AUTL) clinical-to-commercial biopharmaceutical company founded in 2014 by Dr Martin Pule and spun out of University College London. The company designs and manufactures autologous CAR T cell therapies using a proprietary advanced cell programming platform centred on Chimeric Antigen Receptors, proprietary viral vectors, and semi-automated cell manufacturing processes. Its sole commercial product is AUCATZYL (obecabtagene autoleucel / obe-cel), a CD19-directed CAR T therapy approved by the U.S. FDA in 2024, the UK MHRA in 2025, and the European Commission in 2025 for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL); the UK commercial launch occurred in January 2026 following a positive NICE recommendation. Underlying the commercial business is a pipeline of next-generation CAR T candidates (AUTO1/22, AUTO3, AUTO4, AUTO5, AUTO6NG, AUTO8, AUTO9) targeting additional hematologic malignancies, solid tumors, and autoimmune indications including systemic lupus erythematosus and progressive multiple sclerosis.

Autolus generates revenue primarily through sales of AUCATZYL to certified treatment centers and hospital networks in the United States, United Kingdom, and European Union. FY2025 net product revenue was $74.3M, growing to $26.2M in Q1 2026 (versus $9.0M in Q1 2025), with 2026 full-year guidance of $120-135M. Manufacturing is anchored at the Nucleus, a 70,000 sq ft commercial facility in Stevenage, UK, designed for approximately 2,000 batches per year (with capacity doubling planned for 2026), supported by wholly-owned operating subsidiaries in the United States (Autolus Inc., Delaware/Gaithersburg), United Kingdom (Autolus Limited, England), and Germany (Autolus GmbH, Weil am Rhein). The company supplements direct sales with the AutolusAssist U.S. patient support program covering travel, housing, and meal logistics.

Since founding in 2014 with a £30M Series A from Syncona, Autolus has progressed through Series B (£40M, 2016), Series C ($80M, 2018), a NASDAQ IPO in June 2018 ($160.4M), and multiple subsequent public offerings (totaling several hundred million dollars through 2024), supplemented by strategic capital from Blackstone Life Sciences (up to $250M announced in 2021) and a 2024 CAR T collaboration with BioNTech. As of April 2026, the company initiated a 13% workforce reduction to save $15M annually beginning in 2027 alongside $8M of restructuring charges, reflecting a focus on operational efficiency as commercial ramp accelerates.

Autolus firmographics

Firmographics
Name
Autolus
Legal name
Autolus Therapeutics plc
Website
https://autolus.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
501–1,000 employees
Ownership category
akta.pro rank

Autolus industry classification

Industry
Product category
CAR T Cell Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)

Keywords

  • CAR T cell therapy
  • Autologous cell therapy
  • Oncology biopharmaceuticals
  • T cell programming
  • Cell therapy manufacturing

Where Autolus is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Autolus business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Subscription Recurring: No source material with WX-format source IDs was provided to support revenue model details.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Autolus product offering

Product offering

Core offering

Autolus develops, manufactures, and commercializes autologous CAR T cell therapies for cancer and autoimmune diseases. Its lead and only currently approved product is AUCATZYL (obecabtagene autoleucel / obe-cel), a CD19-directed CAR T cell therapy approved by the US FDA in 2024 and subsequently by the UK MHRA and European Commission in 2025 for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. The company also advances a pipeline of next-generation CAR T product candidates (AUTO1/22, AUTO3, AUTO4, AUTO5, AUTO6NG, AUTO8, AUTO9) targeting hematologic malignancies, T-cell lymphomas, solid tumors, and autoimmune indications, supported by an in-house commercial-scale manufacturing facility, The Nucleus, in Stevenage, UK.

Product overview

Autolus Therapeutics is a clinical-to-commercial biopharmaceutical company built around a single unified advanced cell programming platform that powers a portfolio of autologous CAR T cell therapy candidates. The only commercially approved product is AUCATZYL (obecabtagene autoleucel, also known as obe-cel), a CD19-directed CAR T therapy for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL), which received US FDA approval in 2024 and subsequent UK MHRA conditional marketing authorization and European Commission approval in 2025, with UK commercial launch in January 2026. The same platform is extended across a pipeline of next-generation product candidates: AUTO1/22 and AUTO3 (dual CD19/CD22 targeting for B-cell malignancies), AUTO4 and AUTO5 (TRBC1- and TRBC2-targeting for T-cell lymphoma), AUTO6NG (GD2 targeting for neuroblastoma), AUTO8 (dual BCMA/CD19 targeting for multiple myeloma), and AUTO9 (preclinical AML candidate), with obe-cel additionally being evaluated in systemic lupus erythematosus. Together, AUCATZYL forms the approved commercial anchor while AUTO1/22, AUTO3, AUTO4, AUTO5, AUTO6NG, AUTO8, and AUTO9 represent the modular pipeline extensions of Autolus's core CAR T cell programming technology.

Differentiator

Problem solved

Functional benefit

Brands

  • AUCATZYL: Autolus' approved autologous CD19 CAR T-cell therapy (obecabtagene autoleucel / obe-cel) for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
  • Obe-cel
  • AUTO1/22
  • AUTO4 and AUTO5
  • AUTO6NG
  • AUTO8
  • The Nucleus
  • AutolusAssist

Products and services

  • AUCATZYL (obecabtagene autoleucel; obe-cel) Autologous CD19-directed CAR T cell therapy approved by the US FDA (2024), UK MHRA (2025 conditional marketing authorisation), and European Commission (2025) for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (B-ALL); commercially launched in the UK in January 2026. Obe-cel is also being evaluated for indication expansion including systemic lupus erythematosus (SLE).
  • AUTO1/22 Dual-targeting CD19/CD22 CAR T cell therapy candidate in Phase 1 development for pediatric relapsed/refractory B-cell ALL, designed to reduce antigen-negative relapse by simultaneously engaging both CD19 and CD22 on B-cell malignancies.
  • AUTO3 Dual-targeting CD19/CD22 CAR T cell therapy candidate in development for B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL), leveraging Autolus's advanced cell programming platform.
  • AUTO4 TRBC1-targeting CAR T cell therapy candidate in development for T-cell malignancies, including peripheral T-cell lymphoma (PTCL), using a T-cell receptor beta chain constant region 1 (TRBC1) approach to selectively target malignant T-cell clones.
  • AUTO5 TRBC2-targeting CAR T cell therapy candidate in development for T-cell lymphoma, complementing AUTO4 by targeting the TRBC2-positive T-cell population.
  • AUTO6NG GD2-targeting CAR T cell therapy candidate in development for neuroblastoma and other GD2-expressing solid tumors (MAGNETO Phase 1), incorporating next-generation enhancements to Autolus's advanced cell programming platform.
  • AUTO8 Dual-targeting BCMA/CD19 CAR T cell therapy candidate in development for multiple myeloma, intended to address BCMA antigen escape by simultaneously targeting CD19.
  • AUTO9 Preclinical CAR T cell therapy candidate in development for acute myeloid leukemia (AML), expanding Autolus's platform into myeloid malignancies.

Companies that use Autolus

Customer profile

Segments1 record

Ideal customer profiles1 record

Autolus technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Autolus partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves10 records

Expansion highlights6 records

Autolus competitors and assessment

Company assessment

Emerging players

  • Cellectis: Clinical-stage allogeneic CAR T developer using TALEN gene editing, with multiple programs in B-ALL and other hematologic malignancies overlapping with Autolus's pipeline.
  • 2seventy bio: Cell therapy company co-marketing Abecma (idecabtagene vicleucel) with BMS and continuing CAR T pipeline work; operates a similar autologous cell therapy commercial model to Autolus.
  • Caribou Biosciences: Clinical-stage allogeneic CAR T developer using CRISPR-based gene editing; overlapping target indications (B-ALL, B-NHL) with Autolus and a potential longer-term modality competitor.
  • Allogene Therapeutics: Pioneering allogeneic ('off-the-shelf') CAR T cell therapies targeting CD19 and BCMA; if successful, would represent a modality-level competitive threat to Autolus's autologous CAR T platform.
  • Beam Therapeutics: Developing base-edited CAR T cell therapies for hematologic malignancies and rare diseases; an emerging modality competitor to Autolus's engineered T-cell platform.
  • CRISPR Therapeutics: Developing gene-edited allogeneic CAR T cell therapies (e.g., CTX112 for CD19) with partners Vertex and Roche; represents a next-generation competitive modality to Autolus's autologous constructs.

Direct peers

  • Bristol Myers Squibb: Markets Breyanzi (CD19 CAR T) and Abecma (BCMA CAR T) following the Celgene/Juno acquisitions, directly overlapping Autolus's CD19 and pipeline BCMA (AUTO8) franchises; deep commercial reach into US treatment centers.
  • Gilead Sciences (Kite Pharma): Markets Yescarta and Tecartus, the leading commercial CD19 CAR T cell therapies, in direct competition with Autolus's AUCATZYL in B-cell hematologic malignancies; same autologous CAR T modality, same customer base of academic treatment centers.
  • Johnson & Johnson (Janssen): Co-markets Carvykti (ciltacabtagene autoleucel) with Legend Biotech for multiple myeloma, directly competing with Autolus's AUTO8 BCMA/CD19 program; large pharma with global commercialization capability.
  • Novartis: Pioneer of CAR T cell therapy with Kymriah (tisagenlecleucel), the first FDA-approved CAR T, directly competing with AUCATZYL in B-ALL and DLBCL; broad biopharma with deep commercial and manufacturing infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Autolus social profiles

Digital presence

Autolus compliance and trust

Trust signal

Compliance1 record

Autolus financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Autolus leadership team

Management profile

Number of profiles

Profiles31 records

Autolus subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Autolus funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Autolus M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Autolus

What does Autolus do?

Autolus develops, manufactures, and commercializes autologous CAR T cell therapies for cancer and autoimmune diseases. Its lead and only currently approved product is AUCATZYL (obecabtagene autoleucel / obe-cel), a CD19-directed CAR T cell therapy approved by the US FDA in 2024 and subsequently by the UK MHRA and European Commission in 2025 for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. The company also advances a pipeline of next-generation CAR T product candidates (AUTO1/22, AUTO3, AUTO4, AUTO5, AUTO6NG, AUTO8, AUTO9) targeting hematologic malignancies, T-cell lymphomas, solid tumors, and autoimmune indications, supported by an in-house commercial-scale manufacturing facility, The Nucleus, in Stevenage, UK.

Is Autolus a public or private company?

Autolus is a public company. It is classified as public and is currently operating.

When was Autolus founded?

Autolus was founded in 2014. It employs 501 to 1,000 people.

Where is Autolus based?

Autolus is headquartered in London, United Kingdom, in the Europe region.

How does Autolus make money?

One revenue line is on record: subscription Recurring.

Who are Autolus's main competitors?

Emerging players on record are Cellectis, 2seventy bio, Caribou Biosciences, Allogene Therapeutics, Beam Therapeutics and CRISPR Therapeutics. Direct peers are Bristol Myers Squibb, Gilead Sciences (Kite Pharma), Johnson & Johnson (Janssen) and Novartis.

Does Autolus have an API?

No public API is recorded for Autolus.

What industry is Autolus in?

Autolus's product category is CAR T Cell Therapy. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAAKAC, Cell Therapy Manufacturing Services (GMP, autologous/allogeneic). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingAutolus presents 2026 net product revenue outlook of at least $150 millionAutolus Therapeutics expects 2026 net product revenue of at least $150 million, the top of its prior guidance range. Third-quarter Aucatzyl revenue rose 95% to $41.2 million, and nine-month revenue increased 122% to $113.1 million. Manufacturing success exceeds 90% with no capacity limitations.Simply Wall StAnalyst Estimates: Here's What Brokers Think Of Autolus Therapeutics plc (NASDAQ:AUTL) After Its Third-Quarter ReportAutolus Therapeutics reported Q3 revenue of $41m, beating estimates, but a $0.21 loss per share missed by 3.7%. Analysts now forecast 2027 revenue of $196.6m, up 43% from last year, with losses narrowing to $0.70 per share. The consensus price target remains unchanged at $8.36.The Motley FoolAutolus (AUTL) Q3 2026 Earnings Call TranscriptAutolus Therapeutics reported Q3 2026 net product revenue of $41.2 million, up 95% year-over-year, and raised its full-year 2026 revenue guidance to at or exceeding $150 million. The company achieved a 57% gross margin in Q3 and doubled manufacturing output with lower staffing. It also delayed BOBCAT study data to October 2027 for 12-month follow-up.The Motley FoolAutolus (AUTL) Q3 2026 Earnings Call TranscriptAutolus Therapeutics reported Q3 2026 net product revenue of $41.2 million, up 95% year-over-year, and raised its full-year 2026 revenue guidance to at or exceeding $150 million. The company achieved a 57% gross margin in Q3 and doubled manufacturing output with lower staffing. It also delayed BOBCAT study data to October 2027 for 12-month follow-up.GlobeNewswireAutolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026Autolus Therapeutics presented longer-term follow-up data from the CARLYSLE trial of obe-cel in severe refractory SLE at ACR Convergence 2026. In 15 patients, obe-cel was well-tolerated with no severe adverse events, and most achieved DORIS and SLEDAI-2K improvements. The Phase II LUMINA trial is ongoing.Stock TitanAutolus lupus trial: 100% met DORIS in 6+ month cohortAutolus Therapeutics presented longer-term follow-up data from the CARLYSLE trial at ACR Convergence 2026, showing obe-cel was well-tolerated in 15 patients with no severe adverse events. In patients followed for at least six months, 100% achieved DORIS and 6/9 (66.7%) achieved complete renal response, despite severe baseline disease activity.Seeking AlphaAutolus expects full-year 2026 AUCATZYL net product revenue at or above $150M, as BOBCAT data shifts to October 2027 (NASDAQ:AUTL)Autolus Therapeutics reported Q3 2026 net product revenue of $41.2 million and raised its full-year 2026 net product revenue guidance to at or above $150 million. The company also shifted its first BOBCAT progressive MS data presentation to ECTRIMS in October 2027 to ensure at least 12 months of EDSS follow-up, citing KOL feedback.ChartmillAutolus Therapeutics (NASDAQ:AUTL) Q3 2026 Revenue Beat Masks Wider Loss as AUCATZYL Launch Remains in FocusAutolus Therapeutics reported Q3 2026 product revenue of $41.2 million, beating estimates, but EPS of -$0.21 missed by 27%. The company expects full-year AUCATZYL revenue to exceed $150 million, with cash and credit facility funding operations into Q2 2028.Quiver QuantitativeAutolus Q3 Revenue Rises 95% to $41.2 Million | AUTL Stock NewsAutolus Therapeutics reported Q3 2026 net product revenue of $41.2 million, up 95% year-over-year, with total revenue of $41.238 million. The company raised its full-year 2026 outlook, expecting AUCATZYL net product revenue to reach or exceed $150 million. Cash and equivalents totaled $248.4 million at September 30, 2026.Stock TitanAutolus Q3 earnings: revenue rises 95% to $41.2MAutolus Therapeutics reported Q3 2026 net product revenue of $41.2 million, up 95% year-over-year, with gross margin at 57%. The company now expects full-year 2026 AUCATZYL revenue to reach at least $150 million, up from prior guidance.